The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors
Harvard Medical School, Dana-Farber Cancer Institute, Department of Medical Oncology and Brigham and Women’s Hospital, Department of Medicine Dana-Farber/Harvard Cancer Center, Boston, USA
Harvard Medical School, Massachusetts General Hospital, Division of Hematology/Oncology and the Department of Medicine Dana-Farber/Harvard Cancer Center, Boston, USA
Harvard Medical School, Dana-Farber Cancer Institute, Department of Medical Oncology and Brigham and Women’s Hospital, Department of Medicine Dana-Farber/Harvard Cancer Center, Boston, USA
Harvard Medical School, Massachusetts General Hospital, Division of Hematology/Oncology and the Department of Medicine Dana-Farber/Harvard Cancer Center, Boston, USA
Harvard Medical School, Massachusetts General Hospital, Division of Hematology/Oncology and the Department of Medicine Dana-Farber/Harvard Cancer Center, Boston, USA
Harvard Medical School, Massachusetts General Hospital, Division of Hematology/Oncology and the Department of Medicine Dana-Farber/Harvard Cancer Center, Boston, USA
Harvard Medical School, Massachusetts General Hospital, Division of Hematology/Oncology and the Department of Medicine Dana-Farber/Harvard Cancer Center, Boston, USA